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Abstract
The introduction of comparative genomic hybridization (CGH) in
1992 opened new avenues in genomic investigation; in particular,
it advanced analysis of solid tumours, including breast cancer,
because it obviated the need to culture cells before their chromo-
somes could be analyzed. The current generation of CGH analysis
uses ordered arrays of genomic DNA sequences and is therefore
referred to as array-CGH or matrix-CGH. It was introduced in
1998, and further increased the potential of CGH to provide
insight into the fundamental processes of chromosomal instability
and cancer. This review provides a critical evaluation of the data
published on array-CGH and breast cancer, and discusses some
of its expected future value and developments.
Introduction
The precise aetiology of the majority of breast cancers is
elusive, which contrasts with the estimated 5-10% that are
caused by inherited mutations. It is clear that breast cancer
presents as a collection of distinct disease types that differ in
disease progression, treatment response and disease-free
survival. In addition to conventional pathology, emerging
technologies, including micro-arrays, have proven to be
excellent tools in enhancing our understanding of individual
breast cancers and providing assistance in treatment
decision making in clinically relevant subgroups [1]. Initial
observations, indeed most of our current understanding of
chromosome abnormalities came from conventional
cytogenetics. The importance of DNA copy number alter-
ations has been demonstrated in many tumours [2]. More
recently, the results of array comparative genomic hybridi-
zation (array-CGH) analysis of tumour tissues have been
described from several perspectives, including identification
of subgroups (class discovery); identification of genes that
are involved in tumour progression, metastasis and treatment
response; identification of candidate oncogenes (in genetic
amplifications) or tumour suppressors (in homozygous
deletions); and classification of hereditary cancers. A few
studies have also described CGH-based distinctions
between sporadic and familial cases of breast cancer. Among
familial cases, further classification into BRCA1, BRCA2, or
‘other genetic risk factor(s)’ is useful in these families in
general but also for potential additional gene discovery.
Array-CGH technology is a fairly recent and important
upgrade to the groundbreaking (conventional, metaphase
chromosome) CGH technology [3,4], and it is applied to
detect chromosomal DNA copy number alterations (CNA) in
cells or tissues that occur as a result of genomic instability.
CGH technology caused a paradigm shift in (clinical) cyto-
genetics because it avoids the need to culture (tumour) cells.
This is perhaps the main reason why there was considerable
over-representation of information on nonsolid tumours in
cytogenetic databases. Array-CGH can measure genome-
wide copy numbers in an unprecedented and objective
manner. More importantly, complex karyotypes – a hallmark of
many tumours – could be analyzed, including those too
complex for G-banding because CGH readout is done on
normal metaphase chromosomes. Last but not least, CGH
was spectacular step forward because it preceded and did
not require the completion of the human genome (draft)
sequence [5]. It was not until 1998, with knowledge of the
human sequence, that array-CGH began to replace conven-
tional CGH [6], again with some major improvements.
Array-CGH is superbly reviewed elsewhere [7-12], including
its development, initial challenges and ultimate benefits
relative to conventional CGH. However, application of array-
CGH to breast cancer research has not specifically been
addressed. In this review, we discuss some of the prospects
of using array-CGH data to elucidate the process of carcino-
genesis in breast cells and its possible impact on diagnostic
stratification for clinical management. The review addresses
the two goals of array-CGH in breast cancer, which can be
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summarized as follows: (novel) gene discovery in relation to
subtypes, stage, or prognosis of breast cancer; and building
class discovery tools for classification of independent breast
cancers, regardless of the primary aim of identifying genes.
Technical issues
The effective resolution, sensitivity and reproducibility of
array-CGH are constantly being enhanced. Although the
maximal technical resolution of CGH is now approximately
140 kb [13], the resolution of the majority of published array-
CGH studies is in the order of 1 or 2 Mb. This is the average
spacing of probes along the genome but varies considerably
by region. The sensitivity of nearly all platforms is sufficient to
detect one-copy gains and losses, provided that at least 70%
of the cells in the sample are tumour cells. Thus, the
detection limits decrease with a combination of the following
parameters; smaller aberration size (in bases), smaller
aberration amplitude (copy number) and smaller tumour
subclone representation.
Choice of probe sets
Whether to employ probe sets including large insert clones
such as bacterial artificial chromosome (BAC), yeast artificial
chromosome, cosmid and fosmid, as opposed to oligo-
nucleotide (generally 60-70 mers) probe sets, is a major
consideration in the design of array-CGH studies. Most
characteristics of various platforms are described in detail
elsewhere [11]. Clearly, the advantage of using
oligonucleotide provides the greatest flexibility in terms of
availability, which is limited only by knowledge of the DNA
sequence for the species under investigation. Careful
selection of probes is important because the genome
contains many pseudogenes and duplicons; this has been
done for human and mouse up to about 44k [14-16]. The
disadvantage of using short 60-mer probes is the low
hybridization signal, which in theory is a factor of about 2000
times lower than when using the much larger insert BAC
clones, which in turn suffer from variable but high DNA repeat
content that must be quenched by Cot1 (the dominant
fraction of human repetitive DNA sequence)-DNA in the
hybridization mix. In practice, to deal with the low signal to
noise ratio, generally a moving average of about 1–5 Mb is
often applied, which in effect decreases resolution. The
proprietary technology of Agilent (Palo Alto, CA, USA) to
print very high-density arrays enables genome-wide oligo-
array-CGH to be conducted on one microscope slide; this
contrasts with the genome-wide tiling (32k) BAC array, which
uses two slides for the same coverage, doubling the cost for
the profile. One way to overcome this problem is to use a
1 Mb resolution for the complete genome followed by tiling
resolution for the entire genome [17] or for selected regions
of interest [18].
Data analysis
Once an array-CGH profile has been established using any of
a range of adequate protocols available [19-27], one may
decide to use segmentation statistics to determine the
boundaries between and the copy number levels of the
aberrant genomic regions. The underlying biology of copy
numbers has been modelled and assumes that CGH data are
a combination of underlying DNA copy number with a
component of Gaussian noise. One such algorithm uses the
maximum likelihood criterion adjusted using a penalization
term for taking into account model complexity to define
breakpoints [28]. Further, in-depth analyses as well as state-
of-the-art implementation of more complex assumptions have
been described [28-30]. These methods essentially aim to
‘de-noise’ CGH data to enhance breakpoint identification,
such that candidate regions can be identified with greater
precision [18,31-40]. With respect to sensitivity in detecting
gains and losses, it is also critical to use reference samples
that contain a pool of DNA from at least six, unrelated healthy
individuals to suppress the (false) discovery of aberrations in
the control sample, caused by the existence of ‘normal’ inter-
individual variation in copy numbers [41].
This is in accordance with what others have experienced,
namely that advancing to array-CGH leads to much more
data, of similar quality. Having more data per sample poses a
risk for over-fitting, in other words a risk for finding significant
differences between groups by chance alone. One way in
which studies are coping with over-fitting is to increase outlier
thresholds (e.g. from log2ratio = 0.2 to 0.3) or to require a
certain minimum proportion (say 33%) of tumours to share a
particular aberration. This effectively restricts the number of
features (probes) left for comparison but it may not always be
the optimal choice. Nevertheless, this is a method for finding
the dominant features first. We believe that it may be rather
optimistic to set a minimum number of samples for identifying
significant aberrations at, for instance, 33% because this
would easily ignore (not detect) rare breast cancer subtypes
that tend to be under-represented in any particular study.
Array-CGH and expression arrays
Study of gene expression using array technology has garnered
enormous popularity, and continues to generate high-impact
classifiers of tumour type and disease progression [3,42-44].
One must keep in mind that expression arrays and array-CGH
measure different things, which are not always easily
correlated. Expression arrays measure relative abundance of
specific mRNA transcripts and CGH measures relative copy
numbers of genomic DNA regions in a sample. The expression
levels per gene vary enormously even in normal cells,
depending, for instance, on cell type and cell cycle. The
chromosomal fragment (or gene) copy numbers as measured
by array-CGH show much less variation, being one or two
copies in normal cells, and perhaps ranging between none
and 20 copies in tumour cells. It is therefore difficult to
correlate expression data with genomic data directly.
Several studies that have correlated DNA copy number data
(CGH) with expression profiles have been publishedPage 3 of 10
(page number not for citation purposes)
[37,45,46]. They indicate a significant correlation between
copy number and gene expression. In regions of high-level
amplification, 44–62% of genes were reported to be over-
expressed [45,46], compared with just 12% of all genes. The
relation may in some cases be less straightforward, probably
due to the complexity of gene regulation, including pathway
feedback loops. An illustration for this is that breast cancers
with  ERBB2 (17q21) amplification almost invariably
overexpress the gene, which contrasts with only 55% of
cases with a gain of ERBB1 (7p12) [47]. Arrays that support
measurement of DNA as well as RNA include cDNA, oligo-,
and single nucleotide polymorphism (SNP) arrays. The
benefits of dual use are limited because CGH signals
become critically low on short probes; short-probe (high-
complexity) arrays tend to be much more expensive then BAC
arrays; and the reference sample in expression profiling is not
defined but at best held constant across a series of
experiments, as opposed to using a completely 2n (normal
karyotype) reference for array-CGH.
Another important advantage of CGH compared with
expression arrays is that CGH can be conducted reliably
using archival formalin-fixed paraffin-embedded material
[26,48-50]. Although there is evidence that archival material
is also suited to expression analysis, it is only with recently
fixed tissues and only with much effort [51].
Perspective from the tumour (cell line) to
DNA copy number
One major application of CGH is in the analysis of cancer
genomes for genome-wide copy number changes. The
resolution of classic chromosomal CGH is limited by the
highly condensed state of metaphase chromosomes and
further by the optical resolution of the microscopes used to
capture the hybridization signals. In addition, chromosome
condensation may vary from metaphase spread to metaphase
spread. The analysis software normalizes all chromosomes
and assumes linear condensation of all chromosomes. As a
result, the precise location of aberrations becomes uncertain,
which reduces the true effective resolution. In contrast, the
resolution of array-CGH is limited only by the density and
average length of the probe set printed on the array.
Compared with metaphase-CGH, one problem – especially
with earlier versions of array-CGH – was the uncertainty
regarding the genomic location of the clones, which is
dependent on the version of the ‘genome build’ of the human
genome. The ability to detect a change of one copy for both
technologies is roughly similar but highly influenced by the
frequent admixture of nontumour cells in the sample, as well
as by heterogeneity of the tumour tissue (i.e. generally not all
cells will have the same ploidy for all chromosomal regions).
Both factors are important in the analysis of breast cancer,
because breast tumours are heterogeneous and may contain
significant proportions of normal cells. Therefore, as a rule
CGH should be performed only on tissue samples containing
70% or more tumour cells, or one must meet this requirement
through enrichment by macrodissection, (laser capture) micro-
dissection, or flow sorting (fluorescence-activated cell sorting),
followed by some means of DNA amplification [27,52].
Contrary to mRNA content, which for a given gene in a cell
can range between no copies (not expressed) up to many
thousands, the chromosome content of normal (reference)
cells is extremely stable (2n, or diploid); when it is unstable,
as is frequent in cancer cells, it at least remains quite
discrete. This means that extensive regions of the genome
are usually still balanced as in the diploid (2n or unchanged)
or tetraploid (duplicated) state. Unbalanced regions exist
either as homozygous loss (0 copies), heterozygous loss
(1 copy or loss of heterozygosity [LOH]), gain (~3 or 4
copies), and amplifications (~5 or more copies). The
distinction between diploid and triploid or tetraploid genomes
cannot be detected by array-CGH but is best determined by
some independent cell-based method such as fluorescent in
situ hybridization (FISH).
And from DNA copy number back to the
tumour
If we reverse the perspective, array-CGH data can also tell us
something about tumours. This is similar to how cytogenetic
data were used to define subgroups in breast cancer that
correlated with histological type, grade and mitotic activity of
the tumour [53,54]. CGH has been used to classify breast
tumours [55,56]. Because breast cancer is a disease with
high levels of chromosome instability, it can readily be studied
by CGH. Results from various classification studies have
indicated that many gains and losses show recurrences
anywhere between 20% and 80% of all tumours in a class,
depending on the region and the cancer subtype
investigated. Some recurrences exhibit sufficient differential
gains or losses between classes to permit their use for
classification, as in the case of inherited BRCA1 and BRCA2
mutations [55,56]. Certain regions such as 1q and 8q almost
exclusively exhibit gain and rarely loss, whereas 16q often
shows loss but hardly ever gain.
Robust classification procedures require more than counting
frequencies of specific aberrations in various tumour types. It
is important to appreciate that even a significant correlation
of, for instance, 16q loss, which is more frequent in lobular
breast cancer [57], provides limited statistical prediction
power for an individual prospective case. This requires more
rigorous, iterative methods of feature and model selection,
followed by cross-validations and external validations.
Provided that the correct methods are used, we believe that
array-CGH can be useful for identifying distinct breast tumour
subtypes, and can help to define them further, similar to the
study reported by Jonsson and coworkers [58].
CGH and cancer
Cancer is the result of a myriad of genetic and epigenetic
alterations. Identification of the causal perturbations that
Available online http://breast-cancer-research.com/content/8/3/210confer malignant transformation is a central goal in cancer
biology. CGH is a powerful tool for investigating tumours in a
genome-wide manner for such candidate regions. This
strategy was successfully used to identify c-Myc, Her2Neu,
Rab25 and a range of other potential oncogenes [32,59,60].
Vice versa, beginning with knowledge of the causal gene for
the tumour, CGH has been useful in elucidating the extent of
specific as well as recurrent aberrations in tumours such as
those associated with mutations in BRCA1, BRCA2, or P53
in both mouse [61] and human [55,56,58,62,63]. Genomic
instability occurs is still not fully understood. Recently, a
number of possible mechanisms focusing on the fidelity of
chromosome segregation and/or DNA repair have been
proposed [64,65], which may hold some indirect clues as to
how breast tumour CGH profiles in BRCA1 mutation carriers
are different from those in sporadic cases, but they still fail to
explain why. While progress is made to elucidate further the
precise nature of genomic instability, the resulting specificity
of CGH profiles has already been put to good use.
Classification
For instance, CGH profiles have been used in the
classification of breast tumours of unknown causality into
BRCA1 mutation carriers and noncarriers [56]; to delineate
the relationship between synchronous, recurrent and/or meta-
static tumours [55,66-71]; and to define the recurrent
aberrations that appear to be associated with certain clinical
types of breast cancer (e.g. ductal tumours) or with prognosis
or clinical course, or both [17,57,72-79] (Table 1). The study
by Rennstam and coworkers [72] was performed using meta-
phase-CGH, but it clearly demonstrated differential 5-year
survival statistics (56% versus 96%) for distinct CNA tumour
types that were independent of more conventional markers
such as grade, and progesterone receptor or node status.
Jones and coworkers [73] used CGH to subclassify 86
breast tumours of grade III and basal type into groups with
shorter (3.5 years) and longer (15 years) survival.
Others have successfully used metaphase and/or array-CGH
profiles for classification and for mutation pre-screening. Both
Wessels and coworkers [56] and Alvarez and colleagues
[77] conducted studies that were effective in identifying
BRCA1-associated tumours based on CGH profiles of the
tumours. Wessels and coworkers [56] identified 33 out of 34
proven  BRCA1 cases and assigned 10 false-positives
among bilateral breast cancer cases (enriched for elevated
risk), four of which have since been proven to be true BRCA1
mutation carriers (personal communication). This CGH driven
classification has been repeated by Van Beers and
coworkers [55], who reported specific CGH aberrations for
BRCA2-related breast tumours. Also along these lines,
Alvarez and colleagues [77] built a predictor for BRCA1 and
found nearly half of the ‘BRCA1-like’ CGH profiles in their
‘BRCAX’ breast cancer type to be hypermethylated on the
BRCA1 promoter, suggesting that loss of BRCA1 could
have been an initiating event in these tumours.
Candidate gene searches
A number of results of array-CGH analysis of breast tumours
and breast cancer cell lines have been published
[19,21,22,25,27,80-88] (Table 1). Some of these results,
together with large amounts of conventional CGH, FISH and
SKY data of breast cancer, are freely available through the
Progenetix repository [89,90]; NCI and NCBI’s SKY/M-FISH
and CGH Database (2001) [91]; Charité, Berlin University
[92]; and in the supplementary data of many individual
publications. Cytogenetic data has been described [53,54]
and is available for more then 1000 cases at NCBI. The
following discussion illustrates the use and usefulness of
array-CGH for various breast cancer genomes.
A detailed study of 31 advanced archival breast tumours
conducted by Nessling and coworkers [47] elegantly
demonstrates how specificity, sensitivity and resolution are
increased in (matrix) array-CGH compared with conventional
CGH by using the same samples on both platforms. They
identified 44 genes by array-CGH and verified all of them by
PCR in 31 breast tumours. Many of these genes are located
in common altered regions in breast cancer, such as AIB1
(amplified in breast cancer-1) at 20q12 (68% of their cases).
A novel and significant finding was gain of 6p21, containing
CCND3 and  p21/WAF1, in 45% of their cases. There is
ample evidence implicating these genes in cancer, and so a
gain of 6q21 suggests a role for CCND3 and p21/WAF1 in
these cancers also.
Cowell and coworkers [93], using FISH, observed a single
translocation t(3;9) in the MCF10 ‘normal breast’ cell line
associated with an immortalized phenotype. During further
passages this immortalized cell lineage (MCF10A) acquired
additional alterations including t(6;19) and gain of 1q,
detected by CGH. This may suggest that the 1q gain in
breast cancer is an early event and thus may explain why it is
so common (>40% of all breast cancers). It is quite
remarkable for a metaphase-CGH study, even after
verification of the predominant rearrangements by FISH, to
close in on potential tumour genes, such as TAFA1 and p16
in this study. A similar approach looking for recurrent alter-
ations among selected (familiar) breast cancers by
metaphase-CGH did find such a candidate region but it failed
to identify predisposing mutations. It is reasonable to assume
that array-CGH outperforms conventional CGH in this
respect, and is more efficient as a first step toward evaluating
candidate regions, mainly because of increased resolution.
Such candidate gene searches by array-CGH will be valuable
in identifying regions and ultimately genes that are associated
with specific phenotypes such as cell growth, anchorage-
independent survival and metastasis capacity, which are
relevant to and could translate into differential clinical
treatment. Although counterintuitive, it might be important to
recognize that regions of recurrent aberrations may not
contain the mutations sought at all. This is exemplified by the
recurrent aberrations in BRCA1 mutant tumours occurring on
Breast Cancer Research    Vol 8 No 3 van Beers and Petra M Nederlof
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aberrations at the BRCA1 locus itself [56]. Thus, CGH has
helped to uncover some of the intrinsic complexity of tumour
chromosome behaviour, which is still poorly understood.
There are several effective ways to avoid some of the risks
involved in searching complexly rearranged genomes for
candidate genes. One is to map global gene expression onto
genomic positions using comparative expressed sequence
hybridization (CESH) [94]. Another is to focus on known
candidate regions and simultaneously monitor gene
expression as a filtering step to exclude genes. This was the
approach used by Garcia and coworkers [18], who were
prompted by results reported by Ray and colleagues [95] to
study gene expression and CGH at near-tiling resolution of
33 primary breast cancers, 27 breast cancer cell lines and 20
primary ovarian cancers at chromosome 8p11-12 (about 10
Mb), which is a gene-dense region that has been implicated
in various tumour types. By cross-comparison they were able
to define a minimal region of common amplification that
contained four overexpressed and therefore candidate onco-
genes, namely FLJ14299, C8org2, BRF2 and RAB11FIP.
This important finding requires confirmation in independent
series of breast cancer, but the study clearly demonstrates
the power of the CGH approach in combination with other
assays.
At the same time, Prentice and coworkers [17] reported the
same amplified region in 24% of all 382 cases of breast
cancer examined by FISH on tissue micro-arrays followed by
BAC array-CGH in five cases. They reported a minimal
common amplified region in all five cases centromeric to NRG
and  FGFR1 (which are also frequently involved in breast
cancer) that contain just three genes, namely FLJ14299,
SPFH2 (C8org2) and PROSC. Interestingly, only FLJ14299
and  SPFH2 overlap with findings reported by Garcia and
coworkers, suggesting that amplification of one of these, or
both, could represent functional alterations in breast cancer.
The only information available for FLJ14299 is that it
resembles a C2H2 zinc-finger type transcription factor that is
conserved in Drosophila and zebra fish (Danio rerio). For
SPFH2, a potential membrane association is predicted but
unproven (GeneCards; www.genecards.org). Although high-
level amplification in this region correlated with poor survival
in both studies, further studies will be necessary to determine
whether these genes have the capacity of an oncogene.
Available online http://breast-cancer-research.com/content/8/3/210
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Table 1
Studies using array-CGH on breast cancer samples or breast cancer cell lines
Patient source or cell line Array platform Resolution (Mb) Ref.
2 Human cell lines, inclusing breast (BT474) 18,664 oligo nucleotides ~0.15 [16]
BC (n = 5) 32k tiling BAC Sub-Mb [17]
Primary BC (n = 33), BC cell line (n = 27) Genome-wide BAC and high resolution on 8p11-12 ~1.5 [18]
FFPE BC (n = 44) 4153 BAC <1 [24]
Comparison of FFPE with frozen BC 2464 BAC 1.5 [27]
Gain in 47% BC (unpublished results) See Pinkel and coworkers [2] [32]
FFPE BC (n = 31)  471 BAC/PAC 15 [47]
BRCA1 (n = 14), BRCA2 (n = 12), sporadic (n = 26) 3.5k BAC 1 [58]
1 Case report 1777 BAC ~1.5 [66]
24 pairs LCIS + ILC  ~2400 BAC 1.5 [68]
4 synchronous tumours (2 BC and 2 leiomyosarcomas ) 2.5k BAC 1.5 [70]
BC cell line (n = 1)  6k BAC <1 [93]
11 BC cell lines 2464 BAC  (Hum-Array1.14) 1.5 [95]
52 node-negative invasive BC 57 oncogene loci (AmpliOnc™) [96]
Premenopausal BC and radiation (n = 47) 3.5k BAC 1 [107]
16 cell lines (8 of them BC) 9862 SNPs [108]
2 BC cell lines 2560 BAC 1.5 [109]
47 fresh-frozen IDC BC  4134 BAC 0.9 [110]
BAC, bacterial artificial chromosome; BC, breast cancer; CGH, comparative genomic hybridization; FFPE, formalin-fixed paraffin-embedded; IDC,
invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; SNP, single nucleotide polymorphism.Another candidate gene, namely Rab25, was identified
through array-CGH by Cheng and coworkers [32]. Rab25
was found to stimulate anchorage-independent cell survival
and was thus characterized as a potential driver of ovarian
and breast tumour development. Those investigators showed
that the copy number of this 1q22 region correlated with
differential disease-free survival in ovarian cancer patients,
further suggesting that 1q22 is associated with tumour
aggressiveness.
The above examples illustrate the usefulness of array-CGH in
cancer genome research and justify further investigation
involving mapping more candidate cancer genes in a
relatively straightforward and high-throughput manner.
Hereditary breast (and ovarian) cancer and array-CGH
Jonsson and coworkers [58] reported array-CGH findings in
26 cases of hereditary breast cancer and 26 cases of sporadic
breast cancer. They reported one recurrent amplicon
(3q27.1-3) in 71% of 14 BRCA1 breast tumours and one
recurrent amplicon (17q23.3-24.2) in more than 75% of 12
BRCA2 breast tumours. They further identified a set of 169
BAC clones out of their total 3.6k probe set, with sufficiently
differential log ratios between BRCA1, BRCA2 and sporadic
cancer to permit its use for classification of hereditary cases.
However, this classifier will only gain validity after
independent CGH profiles (a validation set) can verify it.
Wessels and colleagues [56] built a molecular classifier with
a performance of 84% for detecting BRCA1 tumours. This
classifier was made using 36 breast tumours from proven
BRCA1 mutation carriers and 30 breast tumours from 30
independent bilateral (elevated risk) breast cancer patients.
This classifier was built from metaphase-CGH but performs
well on array CGH data from BRCA1, BRCA2, sporadic and
BRCAX cases (van Beers EH, unpublished data). A classifier
for BRCA2 has been more problematic. Using metaphase-
CGH, a number of significant and recurrent genomic
aberrations in 25 BRCA2 tumours were described [55] but
the collective predictive power fell short of building a reliable
classifier. We believe that the improved resolution together
with the improved reproducibility of array-CGH might
generate the data necessary for a BRCA2 classifier and
possibly also for other subtypes in the future.
Prognostic information from CGH data
Callagy and coworkers [96] have made an important
contribution to clinical prognostication using an array-CGH
based study. They asked how array-CGH was different
between short-term survivors (<5 years) and long-term
survivors (>10 years). As a result, they found a trio of TOP2a,
ERBB2 and  EMS1 to identify statistically significant
(P = 0.01) differential prognosis among these subgroups.
The differential expression for these genes was further
substantiated by tissue microarray FISH. Quite surprisingly,
their good and bad prognosis groups did not exhibit
differences in grade, size, or oestrogen receptor status –
features that are currently most widely accepted for clinical
prognostication. Because results were not stratified by
tumour type (40 of 52 tumours were invasive ductal
carcinoma), this study does not permit a definitive
conclusion to be drawn about whether this prognostic set of
three genes will be equally valuable in all breast cancer
types. It is worth mentioning that their CGH probe set
consisted of just 57 cancer-gene selected loci. This
suggests that larger probe sets could identify more markers,
and more relevant ones.
Cingoz and colleagues [57] reported a number of recurrent
CGH observations that appear to correlate with certain
disease characteristics. Their list of most frequent gains
includes 1q (55%), 8q (52%) and 20q (29%), which is
similar to many other breast cancer CGH studies and can be
considered general breast cancer copy number gains. Other
regions were distinct to subgroups, such as 16q loss in
seven out of nine (78%) cases of invasive lobular carcinoma
compared with five out of 18 (28%) cases of invasive ductal
carcinoma. Since invasive lobular and ductal carcinoma are
easily distinguished by pathologists, their findings are
probably most important to our understanding of the intrinsic
biology of these different tumour types rather than being
beneficial for diagnosis or clinical decision making.
Pathways of instability
It has long been recognized that several different pathways of
genomic instability exist. Probably most apparent is the
difference between chromosomal instability and microsatellite
instability, the former being more frequent in breast cancer
and the latter being found more often in relation to MLH1
mutations that occur frequently in colon cancers [97]. It
seems likely that certain tumours arrive at an aneuploid state
through a series of events starting with telomere dysfunction,
followed by polyploidization as a cellular rescue/survival
event. Then, as a direct result chromosomes suffer numerous
additional breakage-fusion events, resulting in seemingly
chaotic accumulation of chromosome gains and losses [98].
This scenario is thought to occur frequently in adenocarcino-
mas, including breast cancer, with high-level aneuploidy. With
respect to breast cancer, at least two distinct genome
instability pathways exist and are described in detail in a
recent review by Reis-Filho and coworkers [7].
Some related array-based methods
Any review of the analysis of chromosomal copy numbers in
breast cancer by array-CGH would be incomplete without
mention of some related technologies (e.g. genome-wide
LOH analysis, SNP [haplotype] analysis, CESH [94,99] [also
called expressive genomic hybridization [100]], large-scale
PCR [101] and expression array studies) that often have
similar or overlapping goals, including classification, clinical
prognostication, defining treatment subgroups, finding novel
genes, and so on.
Breast Cancer Research    Vol 8 No 3 van Beers and Petra M Nederlof
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performing genome-wide LOH and SNP analysis, for example
by using Illumina bead-array technology on formalin-fixed
paraffin-embedded tumour tissues [102-104]. These
technologies have a clear advantage over (array) CGH in that
they extract haplotype information in addition to chromosome
copy number. This is especially relevant in chromosomal
uniparental isodisomy, inherited or acquired through mitotic
recombination resulting in variably extended stretches of
homozygosity (i.e. LOH) in the absence of copy number
changes. This has been observed in breast cancer and may
be more frequent then is generally acknowledged [105].
Conclusion
Array-CGH is a reliable, sensitive and high-resolution method
that is highly automated compared with metaphase-CGH,
which it is now replacing; thus, array-CGH is expected to
generate an enormous amount of data in the coming years.
One limitation of all current breast cancer array-CGH studies
is the limited number of samples used per study. It poses the
classic risk for over-fitting for as long as the average study
contains two orders of magnitude more features (i.e. probes)
then samples. One way to tackle this limitation is to have
available the combined data sets or a repository for meta-
analyses of CGH data, histological data, immunostaining
data, clinical data, and so forth.
This review has described the two separate goals of CGH in
breast cancer: gene discovery and class discovery. For both
we have given successful examples. An example of gene
identification is TAFA1, the significance of which in cell trans-
formation was found by array-CGH and was verified
extensively with other methods [93]. These data clearly
prioritize this locus for further functional studies of this
relatively uncharacterized gene. An example of class
prediction by array-CGH is the study Jonsson and coworkers
[58], who built classifiers for BRCA1 and  BRCA2 breast
tumours.
One further conclusion of our review of the array-CGH
literature is that the known heterogeneity of breast cancer
also seems reflected in array-CGH data, such that multiple
types of profiles have been reported, sometimes with clear
but sometimes with less clear associations with known types
of breast cancer. The fact is that the number of described
subtypes of breast cancer increases with increasing
sensitivity and resolution of newer methods. Although novel
technology has no a priori knowledge of the problem
analyzed, one would generally be satisfied if a new
technology would permit enhanced stratification of disease
entities. However, in breast cancer we see a trend toward
discovery of more subgroups that sometimes appear
independent of more traditional classification features, such
as grade, size and immunochemistry (e.g. P53, oestrogen
receptor, progesterone receptor, ERBB2) [96]. One
interpretation is that the within group variability, for instance,
among all grade III cases or all oestrogen receptor negative
cases is still quite large. In our opinion, this could account for
the independent clustering when using CGH data compared
with other tumour characteristics, even when the same
tumour set is studied.
In the near future, when increasing numbers of studies
generate higher resolution data in conjunction with allele-
specific information, such as produced by SNP arrays or
Illumina bead arrays, it may become possible also to elucidate
some effects of genetic backgrounds or genotypes on CGH
as a proxy for genomic instability. Nevertheless, genetic
background appears to impact on CGH profiles [106], and
this type of information should hopefully teach us more about
the biology of chromosomal instability. This touches on a
possible relation between CGH profiles and human genetic
diversity that can best be studied on genome-wide SNP/
CGH arrays and could be extremely useful in locating
putative (median and low risk) breast cancer genes.
Despite the current trend in which oligo array-CGH is
gradually replacing BAC array-CGH because of its flexibility
(clone-less, fast and custom print-on-demand, and probably
the most powerful advantage of assessing copy number and
allele information simultaneously), it seems that BAC arrays
will remain important for profiling DNA from formalin-fixed
material.
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